Loncastuximab tesirine, marketed under the brand name Zynlonta, is a medication used for the treatment of large B-cell lymphoma, particularly in cases where the disease has relapsed or is refractory after at least two prior lines of therapy. Loncastuximab tesirine (Zynlonta) was approved by the U.S. Food and Drug Administration (FDA) on April 23, 2021. This approval provided a new treatment option for patients with large B-cell lymphoma who had not responded to other treatments.
Loncastuximab tesirine is an antibody-drug conjugate (ADC). It combines a monoclonal antibody, which specifically targets the CD19 antigen on the surface of B-cells, with a potent cytotoxic agent. This dual-action approach allows the drug to selectively deliver the cytotoxic agent to cancerous B-cells, reducing the impact on healthy cells and enhancing the effectiveness of the treatment.
Dosage Form: Loncastuximab tesirine is available as an intravenous injection (lpyl 10 mg).
Dosage Instructions:
Administration:
Common Side Effects:
Serious Side Effects:
This antibody-drug conjugate provides a targeted approach to treatment, aiming to minimize the impact on healthy cells while effectively combating cancerous B-cells. As with any medication, it is essential to be aware of the potential side effects and to work closely with healthcare providers to ensure the best possible outcomes.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!